HB0046
/ Zhejiang Huahai Pharma, Huaota Biopharm, Huabo Biopharmaceutical Technology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 08, 2024
Huahai Pharmaceutical: HB0046 injection clinical trial approved [Google translation]
(Hithink RoyalFlush Information Network)
- "Huahai Pharmaceutical...issued an announcement that the company's subsidiaries Shanghai Huaotai Biopharmaceutical Co., Ltd...and Huabo Biotechnology...received the 'Drug Clinical Trial Approval Notice' for HB0046 Injection approved and issued by the National Medical Products Administration....It is reported that HB0046 is a bispecific antibody independently developed based on Huaotai's hybridoma and nanoantibody screening platform, which is composed of the VHH (heavy chain variable region) fragment of anti-CD39 and the monoclonal antibody of anti-CD73."
New trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1